WO2017217753A1 - 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 - Google Patents
퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 Download PDFInfo
- Publication number
- WO2017217753A1 WO2017217753A1 PCT/KR2017/006173 KR2017006173W WO2017217753A1 WO 2017217753 A1 WO2017217753 A1 WO 2017217753A1 KR 2017006173 W KR2017006173 W KR 2017006173W WO 2017217753 A1 WO2017217753 A1 WO 2017217753A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- disease
- culture
- degenerative brain
- preventing
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 65
- 230000003412 degenerative effect Effects 0.000 title claims abstract description 61
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 241000723109 Agathobaculum Species 0.000 title claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 36
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 12
- 241000549949 Agathobaculum butyriciproducens Species 0.000 claims abstract description 9
- 230000028709 inflammatory response Effects 0.000 claims abstract description 9
- 210000004556 brain Anatomy 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 230000015654 memory Effects 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 230000006739 dopaminergic cell death Effects 0.000 claims description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 29
- 238000010171 animal model Methods 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 18
- 230000000968 intestinal effect Effects 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 10
- 230000003920 cognitive function Effects 0.000 abstract description 6
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 208000027061 mild cognitive impairment Diseases 0.000 abstract description 3
- 230000006386 memory function Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 15
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 14
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 13
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 13
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000002265 prevention Effects 0.000 description 11
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 9
- 210000003710 cerebral cortex Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 230000003930 cognitive ability Effects 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 7
- 102100022033 Presenilin-1 Human genes 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 229960000632 dexamfetamine Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000008447 perception Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000006993 memory improvement Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011772 phylloquinone Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 210000001642 activated microglia Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229940039856 aricept Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000006733 dopaminergic cell loss Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 230000009326 social learning Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a strain of Agatobaculum genus having a prophylactic or therapeutic effect of degenerative brain disease and its use.
- acetylcholine degrading inhibitors only improve the decreased cognitive ability and are unable to cure the underlying cause of Alzheimer's disease.
- the long-term administration of the drug is required, in the case of the medicines have problems such as accompanied by various side effects, including liver toxicity, vomiting, loss of appetite. Therefore, the development of new therapeutics that can prevent the progression of degenerative brain disease is an urgent task.
- beta amyloid consists of about 40 amino acids that are believed to be the underlying cause of Alzheimer's disease.
- gamma secretase inhibitors mainly dominated.
- basic research on Alzheimer's disease has been conducted to some extent, but there is almost no case in developing dementia treatment itself.
- Korean Patent No. 1476236 discloses' lactic acid bacteria having prophylactic and / or therapeutic activity of aging and dementia '
- Korean Patent No. 1211331' new tacrolimus derivative, for neuroprotective treatment comprising the derivative A composition, an immunosuppressive composition comprising the derivative, a production method of the derivative, and a production strain of the derivative are disclosed, but as in the present invention, the genus Agatobaculorum has a prophylactic or therapeutic effect of degenerative brain disease. Strain and its use 'is not known at all.
- the present invention has been made by the above-mentioned demands, which can effectively suppress the development and exacerbation of degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, which are recently increasing in modern people, and have no side effects for treating them.
- degenerative brain diseases such as Parkinson's disease and Alzheimer's disease
- a new preventive or therapeutic agent for degenerative brain diseases using a substance that is not toxic to the human body when ingested a new agatobaculorum butyric constitutions ( Agathobaculum) is an intestinal microorganism.
- butyriciproducens SR79 strain improves motor impairment in Parkinson's disease animal model, has an inhibitory effect on encephalopathy response, inhibits the expression of degenerative brain disease markers such as Alzheimer's disease, and improves cognitive ability and memory
- the present invention was completed by confirming that it can be used for preventing or treating degenerative brain disease and improving brain cognitive memory.
- the present invention provides a strain Agagobaculum sp. Having a prophylactic or therapeutic effect of degenerative brain disease.
- the present invention is a degenerative brain disease prevention comprising at least one selected from the group consisting of a strain, the strain-derived vesicles, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture as an active ingredient. Or it provides a pharmaceutical composition for treatment.
- the present invention is a degenerative brain disease containing at least one selected from the group consisting of the strain, the strain-derived vesicles, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture as an active ingredient. It provides a health functional food composition for prevention or improvement.
- the present invention is a degenerative brain disease containing at least one selected from the group consisting of the strain, the strain-derived vesicles, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture as an active ingredient.
- a feed composition for prevention or improvement is provided.
- Intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention has an inhibitory effect on the encephalitis response and has motor control ability, cognitive ability and cognitive ability in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease. Since it shows a memory improving effect, it can be usefully used as a food, medicine or feed for the prevention or treatment of brain diseases including Alzheimer's, Parkinson's disease, mild cognitive impairment, etc., it is very useful in related industries.
- A gas regulator
- B gas line
- D gas cylinder trolley
- E pressurized anaerobic jar ( Oxoid)
- F palladium (catalyst)
- Figure 2 is an intestinal microorganism SR79 strain according to the present invention in the mouse (B6C3-Tg (APPswe / PSEN1dE9) 85DboJ, JAX, 004462) overexpression of APP and PSEN1 genes, which are genes related to Alzheimer's disease in the brain, develop Alzheimer's disease It is expressed as a discriminant index of the cognitive function and memory improvement effect in the novel object recognition test (NORT, A is a new object recognition time, B is a new object recognition number) by administering a.
- B6C3-Tg APPswe / PSEN1dE9 85DboJ, JAX, 004462
- Figure 3 is a mouse induced cognitive impairment by administering LPS, the effect of improving cognitive function and memory in a novel object recognition test (NORT) by administering the strain SR79 strain intestinal microorganism according to the present invention Is a graph.
- the vertical axis shows the cognitive function and memory improvement effect in the new object recognition time as a discriminant index.
- Figure 4 is a mouse induced cognitive impairment by administering LPS (lipopolysaccharide), improve the spatial perception ability and short-term memory in the Y maze test by administering the strain SR79 strain, the enteric microorganism according to the present invention
- LPS lipopolysaccharide
- FIG. 5 shows that in the brain, APP and PSEN1 genes related to Alzheimer's disease are overexpressed, and in the mouse (B6C3-Tg (APPswe / PSEN1dE9) 85DboJ, JAX, 004462) in which Alzheimer's disease develops, SR79 strain which is an enteric microorganism according to the present invention.
- A and graph (B) showing the results of performing immunostaining on hyperactivated astrocytes in the brain by administering to.
- FIG. 6 shows SR79 in which the expression of ionized calcium-binding adapter molecule 1 (Iba-1), a marker for recognizing the activity of microglia, responsible for the inflammatory response in the cerebral cortex of an LPS-administered mouse model It is a graph showing the decrease by administration of the strain.
- Iba-1 ionized calcium-binding adapter molecule 1
- p-APP phosphorylated amyloid precursor protein
- FIG. 9 is a 30-minute analysis of inhibition of the number of dextroamphetamine-induced rotational movements following treatment of the intestinal microorganism SR79 strain in a Parkinson's disease mouse animal model that induced dopaminergic neuron-specific cell death in the brain with 6-OHDA. It is a graph in sum.
- the present invention is a genus Agathobaculum having a prophylactic or therapeutic effect of degenerative brain disease sp.) provide strains.
- the agatobaculorum strain is Agatobakulum butsiprodusense ( Agathobaculum butyriciproducens ), and preferably, the agatobacoolum butyric constitutionsense may be an agatobacoolum butyric yieldsense SR79 strain having an accession number of KCTC13036BP, but is not limited thereto.
- Agagobaculum butyriciproducens SR79 strain according to the present invention is an absolute anaerobic microorganism directly isolated from the intestine of the present inventors in healthy Korean intestines, and new genus and species different from the previously reported standard strains.
- degenerative brain disease in the present invention is a disease that occurs in the brain among degenerative diseases that occur with age, but is not limited thereto.
- degenerative brain diseases are known to be caused by protein aggregation due to neurodegeneration and genetic and environmental factors caused by aging, but neurons are killed, but the exact cause is not known.
- prevention in the present invention means any action that inhibits or delays the onset of degenerative brain disease by administration of the pharmaceutical composition according to the present invention
- treatment means degenerative brain by the administration of the pharmaceutical composition
- Suspicion of disease and onset of disease means any action that improves or beneficially alters the symptoms of the individual.
- the prevention or treatment of the degenerative brain disease can be achieved by the microbial strain having an effect of inhibiting phosphorylation and inflammatory activity of amyloid precursor protein, and behaviorally, Parkinson's disease. And it can be achieved by exhibiting the effects of motor control disorders and cognitive ability and memory in animal models with degenerative brain diseases such as Alzheimer's disease.
- the present invention is a degenerative brain disease containing at least one selected from the group consisting of the strain, the strain-derived vesicles, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture as an active ingredient.
- a prophylactic or therapeutic pharmaceutical composition is provided.
- the composition has an inhibitory effect on movement disorder due to dopaminergic neuronal cell death, or an inhibitory effect on brain inflammatory response, or It may have a cognitive ability and memory improvement effect, but is not limited thereto.
- dopamine in the present invention is a neurotransmitter that transmits a signal in the brain and is known to be related to exercise and movement.
- dopaminergic neuron death in the present invention refers to the loss or degeneration of dopaminergic neurons concentrated in the substantia nigra pars compacta of the midbrain. It is known that it can be produced by injecting 6-OHDA (6-hydroxyldopamine).
- neuroinflammation in the present invention is an important factor that causes degenerative brain disease.
- the inflammatory cells are excessively activated in the brain, the secretion of inflammatory cytokines increases, and the activation of such brain inflammatory responses is increased. It is known that degenerative brain diseases such as brain cell loss and Parkinson's disease and Alzheimer's disease can be induced.
- the SR79 strain provided in the present invention was confirmed to have an inhibitory effect on the brain inflammatory response. It can also improve motor control, cognitive and memory in animal models with degenerative brain diseases such as Parkinson's and Alzheimer's.
- the cognitive impairment of the mouse according to the treatment of the microorganism strain of the present invention and the cognitive function for the new object in the Alzheimer's dementia mouse animal model (Fig. 2 and 3) and Y-shaped maze
- the improvement of spatial perception and short-term memory was confirmed (FIG. 4).
- the expression of the activated microglia marker Iba-1 and the GFAP marker astroglia in the cerebral cortex were significantly reduced by SR79 administration (Figs. 5 and 6), and the control cerebral In the cortex, the expression of phosphorylated amyloid precursor protein (p-APP) in Alzheimer's dementia was significantly increased by LPS, indicating that the risk of developing Alzheimer's disease was increased.
- p-APP phosphorylated amyloid precursor protein
- the intestinal microorganism SR79 strain has an inhibitory effect on the brain inflammatory response, and has an effect of improving motor control, cognitive ability and memory in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease. .
- the pharmaceutical composition of the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- the pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method. Can be used.
- Carriers, excipients and diluents which may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Various compounds or mixtures, including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. .
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, in the strain or the vesicles derived from the strains. , Sucrose or lactose, gelatin and the like are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, wherein the term "pharmaceutically effective amount" of the present invention is for preventing or treating a disease at a reasonable benefit / risk ratio applicable to medical prophylaxis or treatment.
- Sufficient amount means an effective dose level means the severity of the disease, the activity of the drug, the age, weight, health, sex, sensitivity of the patient to the drug, the time of administration of the composition of the invention used, the route of administration and the rate of excretion, The duration of treatment, factors including drugs used in combination or coincidental with the composition of the invention used, and other factors well known in the medical art can be determined.
- compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects.
- the dosage of the pharmaceutical composition of the present invention may be, for example, administered to the mammal including humans at 1.0 ⁇ 10 9 CFU for one day.
- the frequency of administration of the composition of the present invention is not particularly limited, but may be administered once a day or several times in divided doses.
- the dosage does not limit the scope of the invention in any aspect.
- the present invention provides a method for preventing degenerative brain disease, comprising administering the pharmaceutical composition in a pharmaceutically effective amount to a subject having or likely to develop a degenerative brain disease Or provide a method of treatment.
- the composition can be used as an active ingredient of a pharmaceutical composition for preventing or treating degenerative brain disease, the composition can be used for preventing or treating degenerative brain disease.
- the term "individual" of the present invention includes, without limitation, mammals including rats, livestock, humans, etc., which may or may not develop degenerative brain diseases.
- the route of administration of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue.
- the pharmaceutical composition of the present invention is not particularly limited, but may be administered through a route such as oral administration, rectal administration and the like, and may also be administered by other routes depending on the purpose.
- oral administration may denature the intestinal microbial SR79 strain by gastric acid
- the oral composition should be formulated to coat the active agent or protect it from degradation in the stomach.
- the composition may be administered by any device in which the active substance may migrate to the target cell.
- the present invention is a degenerative brain disease containing at least one selected from the group consisting of the strain, the strain-derived vesicles, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture as an active ingredient. It provides a health functional food composition for prevention or improvement.
- the strain is as described above, and may be added to a dietary supplement for the purpose of preventing or improving degenerative brain disease.
- the strain or its culture solution may be added as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
- the food (or nutraceutical) of the present invention may further include ingredients that are commonly added during food production and are food acceptable.
- ingredients that are commonly added during food production and are food acceptable.
- citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and the like may be further included.
- the amount that may be included as an active ingredient of the food (or health functional food) according to the present invention may be appropriately selected according to the age, sex, weight, condition, and symptoms of the disease of a person who wants to prevent or improve degenerative brain disease. Preferably it is included in about 0.01 g to 10.0 g per day of adult standards, by ingesting a food having such a content can be obtained to prevent or improve the degenerative brain disease.
- the present invention provides a method for producing a microbial agent for preventing or treating degenerative brain disease, comprising culturing the strain.
- the method of culturing the strain of the present invention may be cultured according to methods commonly used in the art.
- the microbial agent for preventing or treating degenerative brain disease of the present invention is a genus Agathobaculum as an active ingredient. sp.) strains, preferably Agathobaculum butyriciproducens strains, most preferably Agatobaculum butyiciproducens strains, and most preferably Agatobaculum butyiciproducens SR79 strains having an accession number of KCTC13036BP.
- the microbial agent for preventing or treating degenerative brain disease according to the present invention may be prepared as a solution, powder, suspension, dispersion, emulsion, oily dispersion, paste, dust, propellant or granule, but is not limited thereto.
- the present invention is one or more selected from the group consisting of the strain, the strain-derived endoplasmic reticulum, the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture. It provides a feed composition for preventing or improving degenerative brain disease.
- the strain is as described above, and may be added to the feed composition for the purpose of preventing or improving degenerative brain disease.
- the feed composition may include a feed additive.
- the feed additive of the present invention corresponds to a feed supplement in the Feed Control Act.
- feed in the present invention may refer to any natural or artificial diet, one meal, or the like or a component of the one meal for the animal to eat, ingest and digest.
- the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
- Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
- the composition of the DSM 104 medium is shown in Table 1 below.
- One Cysteine-HCl x H 2 O 0.5 Resazurin 0.001 Salt solution (see Table 2 below) 40 ml Haemin solution (see below) 10 ml Vitamin K 1 solution (see below) 0.2 ml
- the vitamin K1, haemin solution and the cysteine are added after the medium has been boiled and cooled under CO 2 . Adjust pH 7.2 using 8N NaOH. Distribute under N 2 , and autoclave.
- Haemin solution Dissolve 50mg of Hamin in 1ml 1N NaOH.
- Vitamin K 1 Solution Dissolve 0.1ml Vitamin K 1 in 20ml 95% Ethanol.
- Salt solution Composition g / L CaCl 2 ⁇ 2H 2 O 0.25 MgSO 4 7 H 2 O 0.5 K 2 HPO 4 One KH 2 PO 4 One NaHCO 3 10 NaCl 2
- a total of 160 colonies were isolated from Korean female fecal samples by a single colony separation method, and molecular biological identification of these isolated strains was performed by colony PCR. The identified strains were identified as 34 different species in total.
- One week with high butyrate production activity (> 18 mM) was selected for these 160 Korean intestinal absolute anaerobic microorganisms and named SR79.
- the SR79 strain named in the present invention is a novel anaerobic microorganism which is directly classified by the present inventors into a new genus and species different from the previously reported standard strain as an absolute anaerobic microorganism isolated from healthy Korean intestine.
- Physiological / biochemical microorganisms were identified, and their microorganisms were named Agathobaculum butyriciproducens SR79, and the SR79 strain isolated from the present invention was proposed by the present inventors. It was recognized as the standard strain for the genus and species for Agatobaculum butyriciproducens .
- Example 3 Verification of the efficacy of SR79 strain on degenerative brain disease and brain cognitive memory
- mice animal models B6C3-Tg (APPswe / PSEN1dE9) 85DboJ, JAX, 004462) in which Alzheimer's disease is overexpressed in the brain of mice, the genes related to Alzheimer's disease It was.
- the mouse animal model is characterized by beta amyloid deposition in the brain from 5 months of age, characterized by Alzheimer's specific cognitive dysfunction, a sterile (Specific pathogen free (SPF)) environment maintained at 22 ⁇ 24 °C Sterilized feed and water intake freely in the breeding facility, and was maintained while maintaining a 12-hour day and night cycle.
- SPF Specific pathogen free
- the experimental animal group was divided into a group of non-Tg mice not overexpressing APP / PSEN1 and a group of Alzheimer's mice overexpressing APP / PSEN1.
- the SR79 strain was divided into experimental groups administered at a concentration of 2.0 ⁇ 10 8 CFU.
- the number of control and experimental groups in the Alzheimer's diseased mouse group overexpressing the APP / PSEN1 was performed using 12 animals each.
- the group of mice began to be administered to 5 months of age mice, performed a novel object recognition test (NORT) for a new object after vehicle or SR79 strain administration for 9 weeks and brain of the mouse after administration for 13 weeks
- the immunostaining was performed to determine the activity of astrocytes in the brain.
- mice Eight weeks-old male C57BL / 6J mice were used to orally administer 25% glycerol / PBS in the control group and the new microbial SR79 strain grown in the intestine-derived DSM 104 solid medium at 2.0 ⁇ 10 8 CFU daily for 1 week orally.
- the cognitive impairment and Alzheimer's dementia model of mice were induced by intraperitoneally administering LPS (lipopolysaccharide) to SR79 strain and control group at a concentration of 250 ⁇ g / kg daily for 1 week.
- LPS lipopolysaccharide
- the control group 25% glycerol / PBS administration group was divided into LPS administration group and LPS non-administration group was used in the experiment, the number of mice per group was assigned to 8 mice.
- the mice were allowed to freely consume sterilized feed and water in a breeding facility in a specific pathogen free (SPF) environment where the temperature was maintained at 22-24 ° C., and were maintained while maintaining a 12-hour day and night cycle.
- a novel object recognition test (NORT) was performed. Specifically, the APP / PSEN1 overexpressing mouse model of Example 3-1 was administered with control and SR79 strain for 9 weeks, followed by NORT over two days. As shown in 3-2, in the case of LPS administered cognitive impairment model mouse LPS was administered for one week and NORT was performed over two days from the next day. On the first training day, the mice were placed in 41.5 cm x 20 cm x 21.5 cm white boxes and allowed to move freely for 10 minutes. After 10 minutes of adaptation as described above, they were returned to the original cage.
- FIG. 2A Alzheimer's-onset mice overexpressing APP / PSEN1 were found to have reduced the time (FIG. 2A) and the frequency (FIG. 2B) showing interest in new objects significantly compared to normal mice. It was confirmed that the new object search time and the number of searches significantly increased (Students t -test, ** p ⁇ 0.01) (FIG. 2).
- the LPS non-administered group was well aware of both the new square cylinder block and the familiar cylindrical cylinder block, whereas the SR79 strain untreated control group of mice treated with LPS for a week showed cognitive impairment.
- the search time for was significantly reduced, and it was confirmed that it was not able to distinguish between a familiar object and a new object (Students t -test, ** p ⁇ 0.01) (FIG. 3).
- interest in new objects was much higher than in the control group not administered SR79 strain for LPS administration, and it was confirmed that the distinction between familiar and new objects was clearly distinguished (Students t- test, ** p ⁇ 0.01) (FIG. 3).
- the search time is calculated by (time of interest in new objects-time of interest in familiar objects) / (time of interest in new objects + time of interest in familiar objects + time of interest in new objects) Indicated.
- a Y-maze test was performed. Specifically, the Y-maze test is an experiment to determine whether it helps the spatial perception and short-term memory recovery of experimental animals.
- the Y-maze test apparatus is a transparent acrylic plate (width 10). cm, 40 cm in height and 25 cm in height) is composed of a closed maze of Y-shaped, each maze is arranged at a constant angle of 120 degrees to each other. The test was conducted for 10 minutes, and each labyrinth was designated as A, B, and C regions, and experimental experiments were started in one region to freely explore the maze.
- FIG. 5A is a photograph showing the results of immunostaining for activated astrocytes in the brain of an Alzheimer's disease-induced mouse animal model by administration of the SR79 strain
- FIG. 5B shows a vehicle (control) and SR79 strain (SR).
- Iba-1 a marker for the activity of microglia responsible for the brain inflammatory response in the cerebral cortex of LPS model mice, was investigated to investigate the inhibitory effect of SR79 in the LPS-administered mouse model.
- Western blots were performed using calcium-binding adapter molecule 1) antibodies (FIG. 6).
- the cerebral cortical protein of the LPS-administered mouse model was isolated, and Western blot was performed for the phosphorylation of APP (Amyloid precursor protein) using pAPP antibody.
- 6- OHDA 6- hydroxyldopamine Parkinson's disease-induced experimental group by administration
- mice 9-week-old male C57BL / 6J mice were used. The mice were allowed to freely consume sterilized feed and water in a breeding facility in a specific pathogen free (SPF) environment where the temperature was maintained at 22-24 ° C., and were maintained while maintaining a 12-hour day and night cycle.
- the experimental group received oral administration of 25% glycerol / PBS in the control group and the new enteric microorganism SR79 strain from the intestine daily at a concentration of 2.0 x 10 8 CFU for 1 week, followed by 6-OHDA (6-hydroxyldopamine) to the brain. Injection induced dopaminergic neuronal death.
- the populations of the control and experimental groups were performed using 5 and 6 animals, respectively.
- mice were anesthetized using a mixture of ketamine and rompun, and experiments were performed.
- the dopaminergic cell loss of the black matter region of the brain which corresponds to the progression of early Parkinson's disease, was lost.
- 25 mg / kg of desipramine was intraperitoneally administered 30 minutes prior to the administration of 6-OHDA, and a total of 6 ug of 6-OHDA was injected into the striatum of the left brain.
- 6-OHDA was administered directly to the brain, the surgical site was sutured and disinfected, and then the body temperature of the mouse was maintained at 37 ° C. warmer.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Composition | g/L |
Trypticase peptone | 5 |
Peptone | 5 |
Yeast extract | 10 |
Beef extract | 5 |
Glucose | 5 |
K2HPO4 | 2 |
Tween 80 | 1 |
Cysteine-HCl x H2O | 0.5 |
Resazurin | 0.001 |
Salt solution (하기 표 2 참고) | 40 ml |
Haemin solution (하기 참고) | 10 ml |
Vitamin K1 solution (하기 참고) | 0.2 ml |
The vitamin K1, haemin solution and the cysteine are added after the medium has been boiled and cooled under CO2. Adjust pH7.2 using 8N NaOH. Distribute under N2, and autoclave. |
Composition | g/L |
CaCl2·2H2O | 0.25 |
MgSO4·7H2O | 0.5 |
K2HPO4 | 1 |
KH2PO4 | 1 |
NaHCO3 | 10 |
NaCl | 2 |
Claims (10)
- 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속(Agathobaculum sp.) 균주.
- 제1항에 있어서, 상기 아가토바쿨룸 속 균주는 아가토바쿨룸 부트리시프로두센스(Agathobaculum butyriciproducens)인 것을 특징으로 하는 균주.
- 제2항에 있어서, 상기 아가토바쿨룸 부트리시프로두센스는 기탁번호가 KCTC13036BP인 아가토바쿨룸 부트리시프로두센스 SR79 균주인 것을 특징으로 하는 균주.
- 제1항 내지 제3항 중 어느 한 항의 균주, 상기 균주 유래 소포체, 상기 균주의 배양물, 상기 배양물의 농축액, 상기 배양물의 건조물 및 상기 배양물의 추출물로 이루어지는 군에서 선택된 1종 이상을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물.
- 제4항에 있어서, 상기 퇴행성 뇌질환은 알츠하이머병, 파킨슨병, 경도 인지장애, 뇌막염, 중풍, 치매, 헌팅턴병 또는 크로이츠펠트-야콥병인 것을 특징으로 하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물.
- 제4항에 있어서, 상기 조성물은 도파민성 신경세포 사멸에 의한 운동장애의 억제 효과를 가지는 것을 특징으로 하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물.
- 제4항에 있어서, 상기 조성물은 뇌 염증반응에 대한 억제 효과를 가지는 것을 특징으로 하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물.
- 제4항에 있어서, 상기 조성물은 인지 능력 및 기억력 개선 효과를 가지는 것을 특징으로 하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물.
- 제1항 내지 제3항 중 어느 한 항의 균주, 상기 균주 유래 소포체, 상기 균주의 배양물, 상기 배양물의 농축액, 상기 배양물의 건조물 및 상기 배양물의 추출물로 이루어지는 군에서 선택된 1종 이상을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 개선용 건강기능식품 조성물.
- 제1항 내지 제3항 중 어느 한 항의 균주, 상기 균주 유래 소포체, 상기 균주의 배양물, 상기 배양물의 농축액, 상기 배양물의 건조물 및 상기 배양물의 추출물로 이루어지는 군에서 선택된 1종 이상을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 개선용 사료 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018560866A JP6774664B2 (ja) | 2016-06-14 | 2017-06-14 | 退行性脳疾患の予防又は治療効果を有するアガトバキュラム属菌株及びその用途 |
CN201780032490.5A CN109563470B (zh) | 2016-06-14 | 2017-06-14 | 对退行性脑疾病具有预防或治疗效果的agathobaculum属菌株及其应用 |
US16/303,025 US11542468B2 (en) | 2016-06-14 | 2017-06-14 | Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases and use thereof |
EP17813576.0A EP3444330A4 (en) | 2016-06-14 | 2017-06-14 | GENUSAGATHOBACULUM TRIBE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0073585 | 2016-06-14 | ||
KR20160073585 | 2016-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017217753A1 true WO2017217753A1 (ko) | 2017-12-21 |
Family
ID=60664100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/006173 WO2017217753A1 (ko) | 2016-06-14 | 2017-06-14 | 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11542468B2 (ko) |
EP (1) | EP3444330A4 (ko) |
JP (1) | JP6774664B2 (ko) |
KR (1) | KR101799830B1 (ko) |
CN (1) | CN109563470B (ko) |
WO (1) | WO2017217753A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101799830B1 (ko) * | 2016-06-14 | 2017-11-21 | 한국생명공학연구원 | 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 |
KR102218992B1 (ko) * | 2017-12-12 | 2021-02-23 | 한국생명공학연구원 | 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물 |
KR102340392B1 (ko) * | 2018-10-08 | 2021-12-17 | 한국생명공학연구원 | 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도 |
KR101951919B1 (ko) * | 2018-12-07 | 2019-02-25 | (주)에이투젠 | 도파민 분비 증진 기능이 있는 신규한 락토바실러스 루테리 atg-f4 균주, 이를 함유하는 정신질환의 예방 또는 치료용 조성물 |
KR102480148B1 (ko) * | 2020-12-14 | 2022-12-23 | 서울대학교산학협력단 | 인지능력 개선 기능을 가지는 스트렙토코커스 써모필러스 |
CN114790475A (zh) * | 2021-01-25 | 2022-07-26 | 首都医科大学附属北京天坛医院 | 一种与亨廷顿病相关的肠道微生物及其应用 |
KR102337995B1 (ko) | 2021-11-10 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110001493A (ko) * | 2009-06-30 | 2011-01-06 | 일동제약주식회사 | 신규한 락토바실루스 헬베티쿠스, 이의 배양 방법 및 용도 |
US8460648B2 (en) * | 2000-07-25 | 2013-06-11 | Thomas Julius Borody | Probiotic recolonisation therapy |
KR101476236B1 (ko) * | 2012-08-16 | 2014-12-24 | 경희대학교 산학협력단 | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143433A1 (en) * | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
KR101261131B1 (ko) | 2010-08-24 | 2013-05-06 | 이화여자대학교 산학협력단 | 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주 |
CN103857402A (zh) * | 2011-10-11 | 2014-06-11 | 阿基姆医药公司 | 包括厌氧培养的人类肠道微生物群的组合物 |
MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
CN105012349A (zh) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | 一种防治血管性痴呆的益生菌制剂及其制备方法 |
KR101799830B1 (ko) * | 2016-06-14 | 2017-11-21 | 한국생명공학연구원 | 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 |
US11633433B2 (en) * | 2017-07-18 | 2023-04-25 | Keio University | Anti-bacterial composition against TH1 cell-inducing bacteria |
WO2019051380A1 (en) * | 2017-09-08 | 2019-03-14 | Evelo Biosciences, Inc. | BACTERIAL EXTRACELLULAR (EV) VESICLES |
KR102218992B1 (ko) * | 2017-12-12 | 2021-02-23 | 한국생명공학연구원 | 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물 |
BR112020023933A2 (pt) * | 2018-05-24 | 2021-04-27 | Seres Therapeutics, Inc. | composições bacterianas projetadas e usos destas |
AU2019289804A1 (en) * | 2018-06-22 | 2021-01-14 | Basf Se | Compositions for animals and uses thereof |
-
2017
- 2017-06-14 KR KR1020170074744A patent/KR101799830B1/ko active IP Right Grant
- 2017-06-14 US US16/303,025 patent/US11542468B2/en active Active
- 2017-06-14 WO PCT/KR2017/006173 patent/WO2017217753A1/ko active Application Filing
- 2017-06-14 CN CN201780032490.5A patent/CN109563470B/zh active Active
- 2017-06-14 EP EP17813576.0A patent/EP3444330A4/en active Pending
- 2017-06-14 JP JP2018560866A patent/JP6774664B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8460648B2 (en) * | 2000-07-25 | 2013-06-11 | Thomas Julius Borody | Probiotic recolonisation therapy |
KR20110001493A (ko) * | 2009-06-30 | 2011-01-06 | 일동제약주식회사 | 신규한 락토바실루스 헬베티쿠스, 이의 배양 방법 및 용도 |
KR101476236B1 (ko) * | 2012-08-16 | 2014-12-24 | 경희대학교 산학협력단 | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 |
Non-Patent Citations (4)
Title |
---|
AHN, SHARON ET AL.: "Agathobaculum Butyriciproducens Gen. nov. sp. nov., a Strict Anaerobic, Butyrate-producing Gut Bacterium Isolated from Human Faeces and Reclassification of Eubacterium Desmolans as Agathobaculum Desmolans Comb. nov.", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 66, no. 9, 21 June 2016 (2016-06-21), pages 3656 - 3661, XP055450815 * |
CHANG, DONG-HO ET AL.: "Faecalibaculum Rodentium Gen. nov., sp. nov., Isolated from the Faeces of a Laboratory Mouse", ANTONIE VAN LEEUWENHOEK, vol. 108, 2015, pages 1309 - 1318, XP036290308 * |
DATABASE NCBI [O] 6 January 2016 (2016-01-06), XP055463590, Database accession no. KP889099.2 * |
See also references of EP3444330A4 * |
Also Published As
Publication number | Publication date |
---|---|
US11542468B2 (en) | 2023-01-03 |
EP3444330A1 (en) | 2019-02-20 |
JP2019520805A (ja) | 2019-07-25 |
KR101799830B1 (ko) | 2017-11-21 |
EP3444330A4 (en) | 2019-12-25 |
CN109563470A (zh) | 2019-04-02 |
US20190300972A1 (en) | 2019-10-03 |
CN109563470B (zh) | 2023-04-07 |
JP6774664B2 (ja) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017217753A1 (ko) | 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도 | |
WO2018012834A1 (ko) | 퇴행성 뇌질환 또는 대사성 질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도 | |
KR102519483B1 (ko) | 메가스파에라 (megasphera) 속의 세균 균주를 포함하는 조성물 및 이들의 용도 | |
KR102380857B1 (ko) | 신규 유산균 및 이의 용도 | |
KR101799829B1 (ko) | 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도 | |
TWI767013B (zh) | 包含細菌品系之組成物 | |
WO2019199094A1 (ko) | 비만의 예방 또는 치료 효과를 가지는 신규 비피도박테리움 롱검 균주 또는 락토바실러스 람노서스 균주 및 이의 용도 | |
KR101807328B1 (ko) | 경구용 dna 손상 수복 촉진제 및 엘라스타아제 활성 억제제 | |
WO2020116733A1 (ko) | 도파민 분비 증진 기능이 있는 신규한 락토바실러스 루테리 atg-f4 균주, 이를 함유하는 정신질환의 예방 또는 치료용 조성물 | |
WO2019098810A2 (ko) | 신규 유산균 및 이의 용도 | |
KR102269256B1 (ko) | 케피어 유래 프로바이오틱 효모 클루이베로미세스 막시아누스 a5 및 이의 용도 | |
WO2020040382A1 (ko) | 신규한 마그네슘-세리네이트 화합물 및 이의 용도 | |
WO2019117654A1 (ko) | 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물 | |
WO2021107585A1 (ko) | 오미자 추출물 및 아스코르브산 혼합물을 유효성분으로 함유하는 인지기능, 기억력 및 활동성 증진용 조성물 | |
WO2024106716A1 (ko) | 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물 | |
WO2015178653A1 (ko) | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 | |
WO2019190069A1 (ko) | 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물 | |
WO2019117616A1 (ko) | 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물 | |
WO2023068819A1 (ko) | 프로테우스 미라빌리스에 대한 길항 작용 및 신경퇴행성 질환에 대한 우수한 효과를 갖는 신규한 균주 및 이의 용도 | |
WO2022039514A1 (ko) | 락토바실러스 사케이 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물 | |
Wang et al. | Exposure to swainsonine impairs adult neurogenesis and spatial learning and memory | |
WO2022015033A1 (ko) | 페디오코쿠스 이노피나투스 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물 | |
WO2020138769A1 (ko) | 베타카리오필렌을 함유하는 항헬리코박터 식품 조성물 | |
WO2019216465A1 (en) | Composition for prevention of breast cancer comprising cyclic dipeptide and methods of preparation thereof | |
TW202216179A (zh) | 包含細菌菌株之組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2017813576 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018560866 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17813576 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017813576 Country of ref document: EP Effective date: 20181116 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |